SynthesisThe Lancet. Infectious diseases2019
Global burden of melioidosis in 2015: a systematic review and data synthesis.
Synthesis in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 158 citations in OpenAlex.
- Regulation of Type VI Secretion Systems of Burkholderia during transition to intracellular lifestyle.EMBO reports · 2026Article
- Next-Generation Sequencing in Melioidosis: Enhancing Diagnosis, Epidemiology and Antimicrobial Resistance Surveillance.Diagnostics (Basel, Switzerland) · 2026Review
- Dry Season Melioidosis in the Tropical North of Australia.Pathogens (Basel, Switzerland) · 2026Article
- Melioidosis Complicated by Native Valve Endocarditis in a Traveler Returning From Thailand to the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Development and international multicenter evaluation of a second-generation immunochromatography test for the serological diagnosis of melioidosis.PLoS neglected tropical diseases · 2026Article
- Epidemiology, Clinical Features, and Outcomes of Chronic Melioidosis in the Top End of Australia's Northern Territory, 1989-2023.Open forum infectious diseases · 2026Article
- Melioidosis in India: A systematic review of individual cases.IJID regions · 2026Review
- Diabetes Mellitus as a Risk Factor for Severe Disease and Mortality Among Patients with Melioidosis: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Emergence of Human and Animal Melioidosis in Southern Africa, 2018-2021.Tropical medicine and infectious disease · 2026Article
- Distinct clinical profiles of nongonococcal gram-negative septic arthritis: a retrospective analysis from a tertiary center.BMC infectious diseases · 2026Article
- Atypical Presentations in Melioidosis: A Case-Based Review from Endemic Regions.Infectious disease reports · 2026Review
- Serologic Evidence of Exposure to Burkholderia pseudomallei, Nigeria.Emerging infectious diseases · 2026Article
- Article
- Severe acute respiratory distress syndrome due toIDCases · 2026Article
- An interpretable machine learning approach to prognosis of melioidosis pneumonia via computed tomography quantification and clinical data.Scientific reports · 2025Article
- Occupational Laboratory Exposures toPathogens (Basel, Switzerland) · 2025Article
- Melioidosis: a call for recognition as a neglected tropical disease under the Southeast Asia regional neglected tropical disease framework.The Lancet regional health. Southeast Asia · 2025Article
- Adaptation of anMethodsX · 2025Article
- Postexposure Antimicrobial Drug Therapy in Goats Infected with Burkholderia pseudomallei.Emerging infectious diseases · 2025Article
- Two Decades of Melioidosis in India: A Comprehensive Epidemiological Review.Pathogens (Basel, Switzerland) · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byMelioidosis.2019
- Commented on byMelioidosis.2019
Authors and funding
10 authors at 8 institutions in 6 countries.
Funding
Abstract
backgroundMelioidosis is an infectious disease caused by the environmental bacterium Burkholderia pseudomallei. It is often fatal, with a high prevalence in tropical areas. Clinical presentation can vary from abscess formation to pneumonia and sepsis. We assessed the global burden of melioidosis, expressed in disability-adjusted life-years (DALYs), for 2015.
methodsWe did a systematic review of the peer-reviewed literature for human melioidosis cases between Jan 1, 1990, and Dec 31, 2015. Quantitative data for cases of melioidosis were extracted, including mortality, age, sex, infectious and post-infectious sequelae, antibiotic treatment, and symptom duration. These data were combined with established disability weights and expert panel discussions to construct an incidence-based disease model. The disease model was integrated with established global incidence and mortality estimates to calculate global melioidosis DALYs. The study is registered with PROSPERO, number CRD42018106372.
findings2888 articles were screened, of which 475 eligible studies containing quantitative data were retained. Pneumonia, intra-abdominal abscess, and sepsis were the most common outcomes, with pneumonia occurring in 3633 (35·7%, 95% uncertainty interval [UI] 34·8-36·6) of 10 175 patients, intra-abdominal abscess in 1619 (18·3%, 17·5-19·1) of 8830 patients, and sepsis in 1526 (18·0%, 17·2-18·8) of 8469 patients. We estimate that in 2015, the global burden of melioidosis was 4·6 million DALYs (UI 3·2-6·6) or 84·3 per 100 000 people (57·5-120·0). Years of life lost accounted for 98·9% (UI 97·7-99·5) of the total DALYs, and years lived with disability accounted for 1·1% (0·5-2·3).
interpretationMelioidosis causes a larger disease burden than many other tropical diseases that are recognised as neglected, and so it should be reconsidered as a major neglected tropical disease.
fundingEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) Research Grant 2018, AMC PhD Scholarship, The Netherlands Organisation for Scientific Research (NWO), H2020 Marie Skłodowska-Curie Innovative Training Network European Sepsis Academy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.